These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30920394)

  • 1. Rivaroxaban and the EINSTEIN clinical trial programme.
    Cohen AT; Bauersachs R
    Blood Coagul Fibrinolysis; 2019 Apr; 30(3):85-95. PubMed ID: 30920394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.
    Burness CB; Perry CM
    Drugs; 2014 Feb; 74(2):243-62. PubMed ID: 24430916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
    Cohen AT; Dobromirski M
    Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical management of rivaroxaban for the treatment of venous thromboembolism.
    Imberti D; Benedetti R
    Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program.
    Matsuo H; Prins M; Lensing AW; Fujinuma EW; Miyamoto Y; Kajikawa M
    Curr Med Res Opin; 2015 Jun; 31(6):1057-61. PubMed ID: 25851062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study.
    Weitz JI; Bauersachs R; Beyer-Westendorf J; Bounameaux H; Brighton TA; Cohen AT; Davidson BL; Holberg G; Kakkar A; Lensing AW; Prins M; Haskell L; van Bellen B; Verhamme P; Wells PS; Prandoni P;
    Thromb Haemost; 2015 Aug; 114(3):645-50. PubMed ID: 25994838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
    Bookhart BK; Haskell L; Bamber L; Wang M; Schein J; Mody SH
    J Med Econ; 2014 Oct; 17(10):691-5. PubMed ID: 25065536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials.
    Weitz JI; Chan NC
    Thromb Haemost; 2019 May; 119(5):689-694. PubMed ID: 30808045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
    Prins MH; Lensing AW; Brighton TA; Lyons RM; Rehm J; Trajanovic M; Davidson BL; Beyer-Westendorf J; Pap ÁF; Berkowitz SD; Cohen AT; Kovacs MJ; Wells PS; Prandoni P
    Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
    Jugrin AV; Hösel V; Ustyugova A; De Francesco M; Lamotte M; Sunderland T
    J Med Econ; 2016; 19(1):1-10. PubMed ID: 26390231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban for treatment of venous thromboembolism in older adults.
    Mitchell AP; Conway SE
    Consult Pharm; 2014 Sep; 29(9):627-30. PubMed ID: 25203412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension.
    Wells PS; Prins MH; Levitan B; Beyer-Westendorf J; Brighton TA; Bounameaux H; Cohen AT; Davidson BL; Prandoni P; Raskob GE; Yuan Z; Katz EG; Gebel M; Lensing AWA
    Chest; 2016 Nov; 150(5):1059-1068. PubMed ID: 27262225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population.
    Wells PS; Prins MH; Beyer-Westendorf J; Lensing AWA; Haskell L; Levitan B; Laliberté F; Ashton V; Xiao Y; Lejeune D; Crivera C; Lefebvre P; Zhao Q; Yuan Z; Schein J; Prandoni P
    Chest; 2018 Dec; 154(6):1371-1378. PubMed ID: 30201406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results.
    Wells PS; Lensing AWA; Haskell L; Levitan B; Laliberté F; Durkin M; Ashton V; Xiao Y; Crivera C; Lejeune D; Schein J; Lefebvre P
    J Med Econ; 2018 Jun; 21(6):587-594. PubMed ID: 29469638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
    Di Nisio M; Vedovati MC; Riera-Mestre A; Prins MH; Mueller K; Cohen AT; Wells PS; Beyer-Westendorf J; Prandoni P; Bounameaux H; Kubitza D; Schneider J; Pisters R; Fedacko J; Fontes-Carvalho R; Lensing AW
    Thromb Haemost; 2016 Sep; 116(4):739-46. PubMed ID: 27535349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Different Doses of Rivaroxaban and Risk Factors for Bleeding in Elderly Patients with Venous Thromboembolism: A Real-World, Multicenter, Observational, Cohort Study.
    Lu K; Liao QQ; Zhu KW; Yao Y; Cui XJ; Chen P; Bi Y; Zhong M; Zhang H; Tang JC; Yu Q; Yue JK; He H; Zhu ZF; Cai ZZ; Yang Z; Zhang W; Dong YT; Wei QM; He X
    Adv Ther; 2024 Jan; 41(1):391-412. PubMed ID: 37987918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidisciplinary approach to the management of patients with pulmonary embolism and deep vein thrombosis: a consensus on diagnosis, traditional therapy and therapy with rivaroxaban.
    Imberti D; Becattini C; Bernardi E; Camporese G; Cuccia C; Dentali F; Paretti D
    Intern Emerg Med; 2018 Oct; 13(7):1037-1049. PubMed ID: 29520700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.
    Imberti D; Pomero F; Mastroiacovo D
    Blood Transfus; 2020 Jan; 18(1):49-57. PubMed ID: 31184579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.